openPR Logo
Press release

AI-Tailored Footwear: IAMBIC's New Approach to Custom-Fit Shoes

12-02-2024 07:12 PM CET | Fashion, Lifestyle, Trends

Press release from: Getnews

/ PR Agency: Brand Featured
AI-Tailored Footwear: IAMBIC's New Approach to Custom-Fit

How advanced technology is enabling shoe fit personalization with a new level of precision
Image: https://www.getnews.info/uploads/b933fdb82aac48fd4d6ec2b58f0132c2.jpg

IAMBIC MODEL T AI-tailored, made-to-fit shoe

Research shows that 60 to 70% of people wear shoes that do not fit properly (Buldt & Menz, 2018). This statistic isn't surprising, given that the footwear industry has historically relied on standardized sizing to serve billions of unique feet. Yet even when two people share identical measurements, they could need completely different shoes. These facts underscore the complexity of shoe fit design, which has left generations settling for poor fit and pain. AI-driven solutions, such as IAMBIC's custom-fit MODEL T shoe, may offer a data-driven approach to this challenge.

The Problem with Standard Shoes

"Most people have fairly unique foot shapes," explains Dr. Hylton Menz, one of the world's leading podiatry researchers. "Yet, the majority of shoes in stores are designed around a hypothetical average foot." Drawing from over three decades of research, Menz notes that this disconnect can lead to a cascade of issues-from immediate pain to long-term problems like bunions, hammer toes, and compromised knee and back health.

Advanced Technology for AI-Tailored Shoes

IAMBIC's approach combines advanced technology with detailed fit analysis for their custom-fit MODEL T shoe, named a TIME Best Invention. The bespoke fitting process begins with a smartphone-based foot scan where users capture three images of each foot. This analysis generates over 20 distinct measurements to create a detailed digital profile of each foot's unique characteristics. Traditional sizing systems-even with extended sizing options and wide or narrow widths-still rely on standard length and width measurements, failing to capture the true complexity of foot shape.

Precision-Fit Beyond Foot Shape

Even when two people share identical measurements, their optimal footwear needs can differ significantly. The MODEL T's customization process acknowledges this complexity by considering more than just physical dimensions. Beyond the smartphone-based foot scan, users share their comfort preferences and lifestyle details. This data-whether someone prefers a snug or loose fit, more or less cushioning-are crucial because comfort is highly subjective and even millimeter differences can significantly impact fit satisfaction.

Foot Health

This customization system aims to create shoes with optimal fit and comfort for each individual. "IAMBIC's technology is a genuine game-changer," says Menz, explaining how the system "can actually look at the individual, work out the shape of their foot, work out what sort of footwear they need." The potential impact extends beyond individual comfort, as Menz notes: "This has a huge impact on foot health at the population level."

The Verdict

The MODEL T demonstrates how AI-driven analysis can advance footwear customization, addressing longstanding fit challenges that affect both comfort and foot health. Combining precise measurements with comfort preferences creates new possibilities in footwear fitting-transcends traditional sizing and widths to enable comprehensive fit personalization.

More information on custom-fit footwear is available at www.iambic.co [http://www.iambic.co/].

Image: https://www.getnews.info/uploads/f4e3161909870bb58597a937693c8cdb.jpg
Media Contact
Company Name: IAMBIC
Contact Person: Maeve Wang
Email: Send Email [http://www.universalpressrelease.com/?pr=aitailored-footwear-iambics-new-approach-to-customfit-shoes]
Phone: (631) 971-8642
Country: United States
Website: http://www.iambic.co



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release AI-Tailored Footwear: IAMBIC's New Approach to Custom-Fit Shoes here

News-ID: 3767009 • Views:

More Releases from Getnews

Future Electronics Highlights Centon Professional Memory Solutions in New Digital Campaign
Future Electronics Highlights Centon Professional Memory Solutions in New Digita …
Image: https://www.globalnewslines.com/uploads/2025/11/1762787826.jpg Future Electronics, a leading global distributor of electronic components, has launched a new digital campaign featuring the Centon Professional Series of Memory Solutions. Montreal, Canada - November 10, 2025 - Future Electronics, a leading global distributor of electronic components, has launched a new digital campaign featuring the Centon Professional Series of Memory Solutions. The Centon Professional Series delivers reliable, high-performance memory designed for professional workloads and demanding environments. Built with high-quality
Go Find Joy by Rocket Scientist and Innovator Mark L. Fox on Special Flash Sale
Go Find Joy by Rocket Scientist and Innovator Mark L. Fox on Special Flash Sale
A new book from former Space Shuttle Chief Engineer Mark L. Fox has entered the wellness world, and for a limited time, readers can grab it at a special Amazon Flash Sale price. Image: https://authoritypresswire.com/wp-content/uploads/2025/11/mock-00185-88ebd.png In Go Find Joy: The Science of Calm-Erasing Anxiety with Energy Therapy , Fox blends rocket science with neuroscience to offer an accessible solution to the world's #1 mental health struggle: anxiety. From his days engineering spacecrafts to
Selecor Technologies forms Distribution Agreement with Veridian Chemicals to Expand Industrial Reach and Drive Growth in Sustainable Minerals.
Selecor Technologies forms Distribution Agreement with Veridian Chemicals to Exp …
Image: https://www.globalnewslines.com/uploads/2025/11/1762196434.jpg "We are excited to partner with Veridian Chemicals as our sales agent for targeted industrial markets with our Performance Products," said Terry O'Neal, President and COO of Good Earth Minerals. Selecor Technologies, LLC, a division of Good Earth Minerals, LLC (GEM), has partnered with Veridian Chemicals, LLC to expand distribution of sustainable, high-performance mineral products across North America. The partnership combines GEM's mineral innovation with Veridian's market expertise to deliver
Hundreds get ready to escape the real world and live out medieval fantasy in Texas
Hundreds get ready to escape the real world and live out medieval fantasy in Tex …
Image: https://authoritypresswire.com/wp-content/uploads/2025/11/GSP8556.jpg Next week hundreds of Americans will be escaping the stresses and strains of real life to step back in time and live out a medieval fantasy. From Tuesday, November 11 to Sunday, November 16 an area of Texas near Austin will be transformed into a fully immersive experience inspired by fantasies like Game of Thrones, Lord of the Rings and Dungeons and Dragons. Hynafol's Grand Gathering is taking place on

All 5 Releases


More Releases for IAMBIC

HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Per …
The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4-Germany, France, Italy, and Spain-the United Kingdom, and Japan. This growth is attributed to several factors, including the increasing incidence of HER2+ Gastric Cancer, advances in research and development, and innovations in the treatment landscape by various key HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo
HER2+ Non Small Cell Lung Cancer Market Positioned for Accelerated Development T …
The Key HER2+ Non Small Cell Lung Cancer Companies in the market include - Daiichi Sankyo and AstraZeneca, Boehringer Ingelheim, Bayer, Forward Pharmaceuticals, ORIC Pharmaceuticals, Iambic Therapeutics, Mersana Therapeutics/ GSK, Nuvalent, and others. DelveInsight's "HER2+ Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the HER2+ Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the HER2+ Non Small Cell
HER2+ Non-Small Cell Lung Cancer Market: Epidemiology, Therapies, and Key Player …
The HER2+ NSCLC Market (Mutant, Overexpression, and Amplification) in the 7MM was USD ~850 million in 2023 and is expected to increase to USD ~3,110 million by 2034, at a CAGR of 13.2%. Emerging therapies such as Pyrotinib, DZD9008, Mobocertinib (TAK-788), among others, are anticipated to drive significant growth in the HER2+ Non-Small Cell Lung Cancer market in the coming years. DelveInsight has introduced a new report, "HER2+ Non-Small Cell Lung Cancer
HER2+ Gastric Cancer Market Surges as Recent FDA Approvals and Late-Stage Clinic …
The HER2+ Gastric Cancer market is projected to grow significantly, attributed to several factors, including the increasing incidence and innovations in the treatment landscape by various HER2+ Gastric Cancer companies such as Roche, Elevar Therapeutic, BMS, Merck, Daiichi Sankyo, Genentech, Bayer, Loxo Oncology, Eli Lilly, Remegen, AstraZeneca, Hutchison Medipharma, LintonPharm, Qilu Pharmaceutical, Shanghai Henlius Biotech, Seagen, MacroGenics, Merus, OncXerna, Innovent Biologics, and others. DelveInsight's latest report, " [https://www.delveinsight.com/report-store/her2-positive-gastric-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]", provides an in-depth
Her2+ Non Small Cell Lung Cancer Market: Epidemiology, Therapies, Companies, Del …
Her2+ Non Small Cell Lung Cancer therapies, such as Pyrotinib, DZD9008, Mobocertinib (TAK-788), and others, are expected to boost the Her2+ Non Small Cell Lung Cancer Market in the upcoming years. DelveInsight has launched a new report on "Her2+ Non Small Cell Lung Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Her2+ Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as
HER2+ Gastric Cancer Market to Witness Upsurge in Growth During the Forecast Per …
Key HER2+ Gastric Cancer companies in the market include - Roche, Elevar Therapeutic, Bristol-Myers Squibb, Merck, Daiichi Sankyo Inc., Genentech, Bayer/Loxo Oncology, Eli Lilly and Company, Remegen Biosciences, AstraZeneca, Hutchison Medipharma Limited, Jiangsu Alphamab Biopharmaceuticals, MacroGenics/Zai Lab, Merck Sharp & Dohme Corp., Merus N.V., OncXerna Therapeutics, Inc., Innovent Biologics, and others. The HER2+ Gastric Cancer market is projected to grow significantly in the 7MM, which includes the United States, EU4-Germany, France,